fostamatinib + ranitidine

**Fostamatinib + ranitidine** is an investigational combination of the oral spleen tyrosine kinase inhibitor fostamatinib and the H2-receptor antagonist ranitidine. Fostamatinib is a prodrug whose active metabolite, R406, inhibits spleen tyrosine kinase (SYK), impairing B-cell receptor and Fc-activating receptor signaling and thus reducing antibody-mediated cellular responses, particularly platelet destruction. Ranitidine is an H2-blocker that increases gastric pH but, in studies, does not alter fostamatinib's major metabolite (R406) bioavailability or exposure in a clinically relevant way. This combination has been studied to assess the pharmacokinetics and bioavailability of fostamatinib when administered with ranitidine[1][2][3].

Other names

fostamatinibranitidine